APTO - Aptose Biosciences Inc.
1.71
-1.440 -84.211%
Share volume: 670,384
Last Updated: 04-01-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
-0.02%
PREVIOUS CLOSE
CHG
CHG%
$3.15
-1.44
-0.46%
Fundamental analysis
23%
Profitability
0%
Dept financing
23%
Liquidity
44%
Performance
40%
Performance
5 Days
0 0%
1 Month
-48.96%
3 Months
702.06%
6 Months
377.39%
1 Year
16.33%
2 Year
211.02%
Key data
Stock price
$1.71
DAY RANGE
$1.35 - $1.99
52 WEEK RANGE
$0.11 - $3.98
52 WEEK CHANGE
$21.28
DIVIDEND
$0.00
EX-DIVIDEND DATE
02-26-2025
NEXT EARNINGS DATE
04-15-2025
Company detail
CEO: William G. Rice
Region: US
Website: aptose.com
Employees: 40
IPO year: 2006
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing
Region: US
Website: aptose.com
Employees: 40
IPO year: 2006
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing
Aptose Biosciences discovers and develops personalized therapies addressing unmet medical needs in oncology. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and HR MDS. The company also develops luxeptinib, a dual bromodomain and extra-terminal domain motif motif motif protein and kinase inhibitor program.
Recent news
